|Articles|May 6, 2020
Advanced Analytical Workflow Solutions for Monitoring Critical Quality Attributes of Monoclonal Antibodies
Recombinant mAbs tend to be unstable and susceptible to modification/degradation. These mAbs need to be identified/monitored for successful drug development. New advanced LC–MS workflows have been developed to meet such needs.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
3
Norgine Secures Hepatitis Delta Therapy Rights Across Key Region
4
FAQ: What You Need to Know about the Current Antibody Pipeline
5